Ann: Commencement of BNC210 Phase 2 Agitation Trial, page-3

This trial is aimed at Agitated behavioural disturbance in elderly patients, being performed in  specialist geriatric hospital wards. This is a subset of the Generalised Anxiety Disorder (GAD) market that may be more easily commercialised. GAD – which affects seniors – is the most common form of anxiety. 90% of late-life anxiety in the elderly is generalized anxiety disorder. Source:
https://www.belmarrahealth.com/gene...gad-the-leading-anxiety-disorder-for-elderly/
So this trial is aimed at a good part of the GAD market. I suppose Elderly require a separate phase 2 trial. No info on number of participants or dosage. Have to assume it's a Phase 2a pilot study to demonstrate clinical efficacy in this age group. Bionomics trying to show BNC210 is a drug with multiple target markets, trying to make it irresistible to a partner who would take it on to expensive Phase 3 trials.